pan ras antibodies (Proteintech)
Proteintech is a verified supplier 
94
Structured Review
Proteintech
pan ras antibodies
Pan Ras Antibodies, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 21 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pan+ras/pan+Ras+Antibody/bio_rxiv__64898__2026__02__26__708383-232-12-14
Average 94 stars, based on 21 article reviews
Pan Ras Antibodies, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 21 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pan+ras/pan+Ras+Antibody/bio_rxiv__64898__2026__02__26__708383-232-12-14
Average 94 stars, based on 21 article reviews
pan ras antibodies - by Bioz Stars,
2026-09
94/100 stars
Images
Related Articles
FLAG-tag:Article Title: Vitamin K‐dependent gamma‐carboxyglutamic acid protein 1 promotes pancreatic ductal adenocarcinoma progression through stabilizing oncoprotein KRAS and tyrosine kinase receptor EGFR Article Snippet: Next, cells were permeabilized with .1% Saponin (Abmole Bioscience, M9618) and then blocked with 1% BSA at 25°C. .. Primary antibodies against PRRG1 (PA5‐67490, rabbit, Invitrogen), Flag tag (66008‐4‐Ig, mouse, Proteintech), NEDD4 (21698‐1‐AP, rabbit, Proteintech), Ras‐GTP (26909, mouse, NewEast Bioscience), KRAS (12063‐1‐AP, rabbit, Proteintech), Article Title: Dysregulation of RAS proteostasis by autosomal-dominant LZTR1 mutation induces Noonan syndrome–like phenotypes in mice Article Snippet: .. The antibodies used are as follows: HA-tag (catalog 3724), phospho-ERK1/2 (catalog 9101), ERK1/2 (catalog 9102), phospho-MEK1/2 (catalog 9154), MEK1/2 (catalog 8727), phospho-AKT Ser473 (catalog 4060), phospho–AKT Thr308 (catalog 13038), AKT (catalog 9272), and GAPDH (catalog 2118) were purchased from Cell Signaling Technology; FLAG-tag (catalog F1804), RIT1 (catalog HPA053249), and β-actin (catalog A5316) were purchased from Sigma-Aldrich; LZTR1 (catalog sc-390166), NRAS (catalog sc-31), and CUL3 (catalog sc-166110) were from Santa Cruz Biotechnology Inc.; KRAS (catalog OP24) and Article Title: Vitamin K-dependent gamma-carboxyglutamic acid protein 1 promotes pancreatic ductal adenocarcinoma progression through stabilizing oncoprotein KRAS and tyrosine kinase receptor EGFR. Article Snippet: Next, cells were permeabilizedwith .1% Saponin (Abmole Bioscience, M9618) and then blocked with 1% BSA at 25◦C. .. Primary antibodies against PRRG1 (PA5-67490, rabbit, Invitrogen), Flag tag (66008-4-Ig, mouse, Proteintech), NEDD4 (21698-1-AP, rabbit, Proteintech), Ras-GTP (26909, mouse, NewEast Bioscience), KRAS (12063-1-AP, rabbit, Proteintech), Incubation:Article Title: Vitamin K‐dependent gamma‐carboxyglutamic acid protein 1 promotes pancreatic ductal adenocarcinoma progression through stabilizing oncoprotein KRAS and tyrosine kinase receptor EGFR Article Snippet: Next, cells were permeabilized with .1% Saponin (Abmole Bioscience, M9618) and then blocked with 1% BSA at 25°C. .. Primary antibodies against PRRG1 (PA5‐67490, rabbit, Invitrogen), Flag tag (66008‐4‐Ig, mouse, Proteintech), NEDD4 (21698‐1‐AP, rabbit, Proteintech), Ras‐GTP (26909, mouse, NewEast Bioscience), KRAS (12063‐1‐AP, rabbit, Proteintech), Article Title: Hyaluronic Acid-Modified Nanoparticles Self-Assembled from Linoleic Acid-Conjugated Chitosan for the Codelivery of miR34a and Doxorubicin in Resistant Breast Cancer. Article Snippet: In this study, a chitosan-based, self-assembled nanosystem that codelivered microRNA34a (miR34a) and doxorubicin (Dox) with hyaluronic acid (HA) modification (named CCmDH NPs) was developed to reverse the resistance of breast cancer (BCa) cells to Dox.. The CCmDH NPs had a diameter of 180 ± 8.3 nm and a ζ potential of 16.5 mV with a slowrelease effect for 96 h. The codelivery system could protect miR34a from nuclease and serum degradation and transport miR34a and Dox into drug-resistant MCF-7/A cells.. In addition, the CCmDH NPs could inhibit proliferation and promote apoptosis by regulating the protein expression of B-cell lymphoma-2 (Bcl-2) and poly(ADP-ribose) polymerase (PARP) and inhibit invasion, metastasis, and adhesion by regulating E-cadherin, N-cadherin, MMP2, CD44, and Snail molecules. Article Title: Vitamin K-dependent gamma-carboxyglutamic acid protein 1 promotes pancreatic ductal adenocarcinoma progression through stabilizing oncoprotein KRAS and tyrosine kinase receptor EGFR. Article Snippet: Next, cells were permeabilizedwith .1% Saponin (Abmole Bioscience, M9618) and then blocked with 1% BSA at 25◦C. .. Primary antibodies against PRRG1 (PA5-67490, rabbit, Invitrogen), Flag tag (66008-4-Ig, mouse, Proteintech), NEDD4 (21698-1-AP, rabbit, Proteintech), Ras-GTP (26909, mouse, NewEast Bioscience), KRAS (12063-1-AP, rabbit, Proteintech), Nucleic Acid Electrophoresis:Article Title: Hyaluronic Acid-Modified Nanoparticles Self-Assembled from Linoleic Acid-Conjugated Chitosan for the Codelivery of miR34a and Doxorubicin in Resistant Breast Cancer. Article Snippet: In this study, a chitosan-based, self-assembled nanosystem that codelivered microRNA34a (miR34a) and doxorubicin (Dox) with hyaluronic acid (HA) modification (named CCmDH NPs) was developed to reverse the resistance of breast cancer (BCa) cells to Dox.. The CCmDH NPs had a diameter of 180 ± 8.3 nm and a ζ potential of 16.5 mV with a slowrelease effect for 96 h. The codelivery system could protect miR34a from nuclease and serum degradation and transport miR34a and Dox into drug-resistant MCF-7/A cells.. In addition, the CCmDH NPs could inhibit proliferation and promote apoptosis by regulating the protein expression of B-cell lymphoma-2 (Bcl-2) and poly(ADP-ribose) polymerase (PARP) and inhibit invasion, metastasis, and adhesion by regulating E-cadherin, N-cadherin, MMP2, CD44, and Snail molecules. Polyacrylamide Gel Electrophoresis:Article Title: Hyaluronic Acid-Modified Nanoparticles Self-Assembled from Linoleic Acid-Conjugated Chitosan for the Codelivery of miR34a and Doxorubicin in Resistant Breast Cancer. Article Snippet: In this study, a chitosan-based, self-assembled nanosystem that codelivered microRNA34a (miR34a) and doxorubicin (Dox) with hyaluronic acid (HA) modification (named CCmDH NPs) was developed to reverse the resistance of breast cancer (BCa) cells to Dox.. The CCmDH NPs had a diameter of 180 ± 8.3 nm and a ζ potential of 16.5 mV with a slowrelease effect for 96 h. The codelivery system could protect miR34a from nuclease and serum degradation and transport miR34a and Dox into drug-resistant MCF-7/A cells.. In addition, the CCmDH NPs could inhibit proliferation and promote apoptosis by regulating the protein expression of B-cell lymphoma-2 (Bcl-2) and poly(ADP-ribose) polymerase (PARP) and inhibit invasion, metastasis, and adhesion by regulating E-cadherin, N-cadherin, MMP2, CD44, and Snail molecules. Blocking Assay:Article Title: Hyaluronic Acid-Modified Nanoparticles Self-Assembled from Linoleic Acid-Conjugated Chitosan for the Codelivery of miR34a and Doxorubicin in Resistant Breast Cancer. Article Snippet: In this study, a chitosan-based, self-assembled nanosystem that codelivered microRNA34a (miR34a) and doxorubicin (Dox) with hyaluronic acid (HA) modification (named CCmDH NPs) was developed to reverse the resistance of breast cancer (BCa) cells to Dox.. The CCmDH NPs had a diameter of 180 ± 8.3 nm and a ζ potential of 16.5 mV with a slowrelease effect for 96 h. The codelivery system could protect miR34a from nuclease and serum degradation and transport miR34a and Dox into drug-resistant MCF-7/A cells.. In addition, the CCmDH NPs could inhibit proliferation and promote apoptosis by regulating the protein expression of B-cell lymphoma-2 (Bcl-2) and poly(ADP-ribose) polymerase (PARP) and inhibit invasion, metastasis, and adhesion by regulating E-cadherin, N-cadherin, MMP2, CD44, and Snail molecules. Membrane:Article Title: Hyaluronic Acid-Modified Nanoparticles Self-Assembled from Linoleic Acid-Conjugated Chitosan for the Codelivery of miR34a and Doxorubicin in Resistant Breast Cancer. Article Snippet: In this study, a chitosan-based, self-assembled nanosystem that codelivered microRNA34a (miR34a) and doxorubicin (Dox) with hyaluronic acid (HA) modification (named CCmDH NPs) was developed to reverse the resistance of breast cancer (BCa) cells to Dox.. The CCmDH NPs had a diameter of 180 ± 8.3 nm and a ζ potential of 16.5 mV with a slowrelease effect for 96 h. The codelivery system could protect miR34a from nuclease and serum degradation and transport miR34a and Dox into drug-resistant MCF-7/A cells.. In addition, the CCmDH NPs could inhibit proliferation and promote apoptosis by regulating the protein expression of B-cell lymphoma-2 (Bcl-2) and poly(ADP-ribose) polymerase (PARP) and inhibit invasion, metastasis, and adhesion by regulating E-cadherin, N-cadherin, MMP2, CD44, and Snail molecules. Saline:Article Title: Hyaluronic Acid-Modified Nanoparticles Self-Assembled from Linoleic Acid-Conjugated Chitosan for the Codelivery of miR34a and Doxorubicin in Resistant Breast Cancer. Article Snippet: In this study, a chitosan-based, self-assembled nanosystem that codelivered microRNA34a (miR34a) and doxorubicin (Dox) with hyaluronic acid (HA) modification (named CCmDH NPs) was developed to reverse the resistance of breast cancer (BCa) cells to Dox.. The CCmDH NPs had a diameter of 180 ± 8.3 nm and a ζ potential of 16.5 mV with a slowrelease effect for 96 h. The codelivery system could protect miR34a from nuclease and serum degradation and transport miR34a and Dox into drug-resistant MCF-7/A cells.. In addition, the CCmDH NPs could inhibit proliferation and promote apoptosis by regulating the protein expression of B-cell lymphoma-2 (Bcl-2) and poly(ADP-ribose) polymerase (PARP) and inhibit invasion, metastasis, and adhesion by regulating E-cadherin, N-cadherin, MMP2, CD44, and Snail molecules. |